CF
KYMR icon

Corebridge Financial’s Kymera Therapeutics KYMR Stock Holding History

Corebridge Financial’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,002
Closed -$630K – 1478
2025
Q1 		$630K Sell
23,002
-341
-1% -$12.4K ﹤0.01% 1473
2024
Q4 		$939K Sell
23,343
-442
-2% -$20K 0.01% 1352
2024
Q3 		$1.13M Sell
23,785
-146
-0.6% -$6.45K 0.01% 1307
2024
Q2 		$714K Buy
+23,931
New +$829K ﹤0.01% 1512

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Corebridge Financial's KYMR Position: Q2 2025 in Review

Corebridge Financial sold out of Kymera Therapeutics (KYMR) in Q2 2025, closing a stake of 23,002 shares — an estimated $630K sold.

Corebridge Financial first reported a position in KYMR in Q2 2024 and held it in 4 quarters. The position peaked at $1.13M in Q3 2024. 210 funds tracked by Wall St. Rank hold KYMR as of Q2 2025.

  • Corebridge Financial reported no remaining Kymera Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 23,002 Kymera Therapeutics shares in Q2 2025, an estimated $630K.
  • Corebridge Financial first reported a position in Kymera Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Kymera Therapeutics position peaked at $1.13M in Q3 2024.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.